ThursdayMar 24, 2022 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year. Psilocybin could lead to significant, durable improvements in depression. Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes well for Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company that is focused on revolutionizing mental health care, including major depressive disorder (“MDD”). “Previous studies by Johns Hopkins Medicine researchers…

Continue Reading

WednesdayMar 23, 2022 3:23 pm

American Hospital Association Calls on Congress to Address Shortage of Behavioral Healthcare Providers

The American Hospital Association (AHA) is urging the Senate Finance Committee to strengthen financial support programs that assist healthcare systems to address the shortage of providers of behavioral healthcare. The organization recently penned a statement to Congress highlighting how the coronavirus pandemic increased the demand for care and aggravated the behavioral health crisis. All individuals, but particularly children and adolescents, are experiencing high rates of depression, anxiety and substance use disorder, among other mental issues. However, barriers hinder them from acquiring proper care. Currently, health systems and hospitals are finding it hard to offer sufficient behavioral healthcare services to youths…

Continue Reading

TuesdayMar 22, 2022 12:36 pm

Rates of PTSD High Among Athletes

While almost every individual will experience a traumatic event at least once in their lifetime, not everybody will develop post-traumatic stress disorder (“PTSD”). Research has found that unlike the general population, some groups do undergo experiences that make them more susceptible to PTSD. For instance, members of the military have some of the highest rates, at 38%, with 33% of ICU nurses and 18% of nurses also meeting the diagnostic criteria for post-traumatic stress disorder. Studies have now found that this disorder is also common in athletes, with estimates ranging from 13% to 25%. PTSD is classified with stressor and…

Continue Reading

MondayMar 21, 2022 12:25 pm

Serious Mental Disorders Tied to Increased Heart-Disease Risks

A new study has found that individuals who have been diagnosed with mental health conditions such as schizoaffective disorder, bipolar disorder or schizophrenia have a heightened risk of cardiovascular disease when they are young, in comparison to adults who haven’t been diagnosed with these mental conditions. Schizoaffective disorder is a continuous duration of illness in which an individual experiences major mood episodes, which could be depressive or manic. Individuals with this disorder meet the criteria for schizophrenia. Schizophrenia is a mental illness that causes delusions, hallucinations or disorganized speech while bipolar disorder is a mental disorder that causes untempered shifts…

Continue Reading

FridayMar 18, 2022 2:58 pm

How the Coronavirus Pandemic Has Affected Chronic Illnesses

The coronavirus pandemic has significantly changed the health landscape in the United States these past two years, especially when it comes to the management of chronic illnesses such as diabetes. The pandemic has raised the threat of more serious ailments for many individuals with underlying health conditions. This will likely contribute to an increase in mortality for some of the leading causes of death, including diabetes and Alzheimer’s disease. Dr. Robert Gabbay of the American Diabetes Association stated that most of the issues and conditions that need to be addressed with diabetes had been delayed for a long period, noting…

Continue Reading

FridayMar 18, 2022 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences

Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and…

Continue Reading

ThursdayMar 17, 2022 2:14 pm

Study Discovers Link Between Metabolism, the Circadian Rhythm

New research on addiction conducted by scientists from the University of California-Irvine has discovered links between metabolism and the circadian rhythm. The circadian clock relies on various interactions between systems to maintain regular timing and is entwined with metabolism. Environmental and/or genetic changes can distort communication between organs, which modifies the rhythm of various activities. Professor Emiliana Borrelli, the study’s author, stated that the group’s discovery showed a connection between metabolic dysfunction and substance-use disorders. Borrelli, who has specialized in molecular genetics and microbiology, collaborated with the late Professor Paolo Sassone-Corsi on this study. Substance-use disorders affect millions of individuals…

Continue Reading

ThursdayMar 17, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…

Continue Reading

ThursdayMar 17, 2022 9:00 am

Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program

Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke Companies in diagnostic space posting record revenues, double-digit YOY increases Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programs Competitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, and skin changes Clinical research reveals that volatile blood sugar fluctuations are a primary risk factor for rapidly rising cases of metabolic syndrome - a cluster of diseases that include diabetes, dementia, cardiovascular issues, and stroke. Abbott (NYSE: ABT), a global healthcare company targeting the…

Continue Reading

WednesdayMar 16, 2022 1:18 pm

Researchers Give Recommendations on How to Improve Diagnosis, Treatment of Prediabetes

Prediabetes is a condition that occurs when an individual’s blood sugar levels aren’t high enough to meet the type 2 diabetes threshold but are still higher than normal. Experts believe that when the condition is diagnosed while in its early stages, regular exercise and changes to an individual’s lifestyle may delay or prevent the development of type 2 diabetes as well as the heightened risks the disease poses for kidney failure, stroke, heart disease and nerve damage. However, it is unlikely that people in the United States with prediabetes are being diagnosed and treated in the early stages to prevent…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050